phenopyrazone profile

Phenopyrazone is a pyrazolidinedione derivative that was first synthesized in the 1950s. It is a nonsteroidal anti-inflammatory drug (NSAID) that acts as an analgesic, antipyretic, and anti-inflammatory agent. It is thought to work by inhibiting the production of prostaglandins, which are chemicals that contribute to pain, inflammation, and fever. Phenopyrazone was widely used to treat a variety of inflammatory conditions, including rheumatoid arthritis, osteoarthritis, gout, and acute pain. However, it was associated with a number of serious side effects, including gastrointestinal bleeding, liver damage, and blood disorders. As a result, its use has declined significantly in recent years and it is now considered a second-line treatment option. Research on phenopyrazone continues, as it is studied for its potential to reduce the risk of cardiovascular disease. Some studies have shown that it may have anti-thrombotic properties and can help to lower blood pressure. However, further research is needed to confirm these findings. '

phenopyrazone: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	92956
SCHEMBL ID	25466
MeSH ID	M0056225

Synonym
1,4-diphenylpyrazolidine-3,5-dione
einecs 222-324-3
1,4-diphenyl-3,5-pyrazolidinedione
kr 122
diphenox
phenopyrazone
3,5-pyrazolidinedione, 1,4-diphenyl-
1,4-diphenyl-3,5-dioxo-pyrazolidin [german]
3426-01-5
1,4-diphenyl-3,5-dioxo-pyrazolidin
unii-19ovl5jyll
19ovl5jyll ,
phenopyrazone [who-dd]
phenopyrazone [mi]
SCHEMBL25466
phenopyrazon
Q27252122
DTXSID10871889

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	13 (100.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	13 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
phenytoin [no description available]	1.96	1	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
hydralazine Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.	1.96	1	azaarene; hydrazines; ortho-fused heteroarene; phthalazines	antihypertensive agent; vasodilator agent
phenylbutazone Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.	3.9	13	pyrazolidines	antirheumatic drug; EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor; metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
procainamide Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.	1.96	1	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker
penicillamine Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.. penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.	1.95	1	non-proteinogenic alpha-amino acid; penicillamine	antirheumatic drug; chelator; copper chelator; drug allergen
aminopyrine Aminopyrine: A pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of AGRANULOCYTOSIS. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of CYTOCHROME P-450 metabolic activity in LIVER FUNCTION TESTS.. aminophenazone : A pyrazolone that is 1,2-dihydro-3H-pyrazol-3-one substituted by a dimethylamino group at position 4, methyl groups at positions 1 and 5 and a phenyl group at position 2. It exhibits analgesic, anti-inflammatory, and antipyretic properties.	6.95	1	pyrazolone; tertiary amino compound	antipyretic; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
methyldopa Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.. alpha-methyl-L-dopa : A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.	1.95	1	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent
glycosides [no description available]	1.95	1

Condition	Relationship Strength	Studies
Dermatitis, Eczematous [description not available]	1.93	1
Leg Ulcer Ulceration of the skin and underlying structures of the lower extremity. About 90% of the cases are due to venous insufficiency (VARICOSE ULCER), 5% to arterial disease, and the remaining 5% to other causes.	1.93	1
Stasis Ulcer [description not available]	1.93	1
Varices [description not available]	2.64	3
Eczema A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).	1.93	1
Varicose Ulcer Skin breakdown or ulceration in the drainage area of a VARICOSE VEIN, usually in the leg.	1.93	1
Varicose Veins Enlarged and tortuous VEINS.	2.64	3
Vascular Diseases Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.	2.35	2
Adverse Drug Event [description not available]	1.96	1
Libman-Sacks Disease [description not available]	3.45	8
Symptom Cluster [description not available]	2.87	4
Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.	3.45	8
Syndrome A characteristic symptom complex.	2.87	4
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	1.96	1
Bone Marrow Diseases Diseases involving the BONE MARROW.	1.95	1
Hypersensitivity, Type III [description not available]	1.95	1
Nephritis Inflammation of any part of the KIDNEY.	1.95	1
Lupus Erythematosus, Chronic Cutaneous [description not available]	1.95	1
Lupus Erythematosus, Discoid A chronic form of cutaneous lupus erythematosus (LUPUS ERYTHEMATOSUS, CUTANEOUS) in which the skin lesions mimic those of the systemic form but in which systemic signs are rare. It is characterized by the presence of discoid skin plaques showing varying degrees of edema, erythema, scaliness, follicular plugging, and skin atrophy. Lesions are surrounded by an elevated erythematous border. The condition typically involves the face and scalp, but widespread dissemination may occur.	1.95	1
Cardiac Diseases [description not available]	1.95	1
Cardiac Failure [description not available]	1.95	1
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	1.95	1
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	1.95	1
Autoimmune Disease [description not available]	1.95	1
Pyrexia [description not available]	1.95	1
Carditis [description not available]	1.95	1
Pleuropericarditis Inflammation of both the PERICARDIUM and the PLEURA.	1.95	1
Pleurisy INFLAMMATION of PLEURA, the lining of the LUNG. When PARIETAL PLEURA is involved, there is pleuritic CHEST PAIN.	1.95	1
Phlegmasia Alba Dolens Inflammation that is characterized by swollen, pale, and painful limb. It is usually caused by DEEP VEIN THROMBOSIS in a FEMORAL VEIN, following PARTURITION or an illness. This condition is also called milk leg or white leg.	1.95	1
Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.	1.95	1
Fever An abnormal elevation of body temperature, usually as a result of a pathologic process.	1.95	1
Myocarditis Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies.	1.95	1
Pericarditis Inflammation of the PERICARDIUM from various origins, such as infection, neoplasm, autoimmune process, injuries, or drug-induced. Pericarditis usually leads to PERICARDIAL EFFUSION, or CONSTRICTIVE PERICARDITIS.	1.95	1
Pleural Effusion Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.	1.95	1
Thrombophlebitis Inflammation of a vein associated with a blood clot (THROMBUS).	1.95	1
Acute Disease Disease having a short and relatively severe course.	1.95	1
Lupus Vulgaris A form of cutaneous tuberculosis. It is seen predominantly in women and typically involves the NASAL MUCOSA; BUCCAL MUCOSA; and conjunctival mucosa.	2.37	2
Diathesis [description not available]	1.97	1
Rheumatism [description not available]	1.97	1
Rheumatic Diseases Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement.	1.97	1

phenopyrazone

Description

Cross-References

Synonyms (18)

Research

Studies (13)

Market Indicators

Research Demand Index: 11.81

Study Types